NOTCH1 and adrenal cortex carcinoma: This agent has been studied in several phase I CTs of relapsed or refractory lymphoid malignancies, solid tumors, and previously treated metastatic colon cancers (NCT01778439, NCT01703572, NCT03031691), with some efficacy signals in patients with ACC associated with Notch1-activating mutations [212,213].